ArticleFrontiers in bioengineering and biotechnology2026
Closing the implementation gap: a harmonised EU framework for synthetic nucleic acid screening and customer verification.
Article in Frontiers in bioengineering and biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Synthetic nucleic acid technologies underpin modern biological research and biomanufacturing. However, their growing accessibility through commercial synthesis services, benchtop devices, and AI-assisted design tools creates significant dual-use biosecurity risks. This paper presents a harmonised EU biosecurity screening framework operationalised through the proposed EU Biotech Act I (December 2025), evaluating two complementary control mechanisms: Know Your Customer (KYC) verification and sequence screening against Sequences of Concern (SOC). We find that existing voluntary frameworks leave systematic coverage gaps that binding EU-level obligations, anchored to ISO 20688-2:2024, would substantively address - particularly for smaller providers and benchtop devices. We argue that near-term EU action offers a time-sensitive opportunity to shape global synthetic biology governance before regulatory fragmentation becomes entrenched.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.